Cormorant Asset Management added 251,600 shares in Rapport Therapeutics; the reported position value increased by approximately $61.38 million over the prior quarter. The change represents 0.31% of ...
Rapport Therapeutics (NASDAQ:RAPP) traded higher on Friday after Goldman Sachs assigned the neurology drug developer a Buy rating and a 12-month price target of $51 based on mid-stage trial data the ...
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
ABSTRACT: The Sabodala mine uses laterite in the tailings and water dams as the main material for the dikes of the hydraulic structures and as a sealing layer (physical barrier) to limit the seepage ...
Imagine this: You’re a writer working on a script or—better yet—you’ve just finished your latest draft. You’ve spent months crafting characters, structuring plot, and developing story. You put the ...
(RTTNews) - Rapport Therapeutics, Inc. (RAPP), a clinical-stage biotechnology company focused on central nervous system disorders, on Thursday, announced promising results from its Phase 1 PET and MAD ...
Apple Inc. (NASDAQ:AAPL) CEO Tim Cook's approach to building a relationship with Donald Trump during his presidency reportedly gave Cupertino unique advantages over competitors. Other tech leaders may ...
The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks the study design. Rapport has been evaluating the TARPγ8-targeting drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results